Jin Medical International Ltd. ZJYL · NASDAQ
$2.05 +1.48% (+$0.03)
Summary
35 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
What to watch
- Repaying its net debt would take 12.3 years of operating profit.
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
- It earns only 1.1 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.9 USD for 1 USD of yearly profit. Over the last five years it was 82.6 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue grew by 5.0% a year over 5 years. Over the last 3 years it grew by 2.5% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Research and development 9.0 USD
- Sales and administration 19 USD
- Taxes and other -3.8 USD
- Net profit 5.9 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 5.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other Products Member 100%
By region
The company reports no revenue by region.
Other Products Member brings in 100% of revenue.
Segments in detail